TY - JOUR
T1 - Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region
AU - Schlepckow, Kai
AU - Monroe, Kathryn M.
AU - Kleinberger, Gernot
AU - Cantuti-Castelvetri, Ludovico
AU - Parhizkar, Samira
AU - Xia, Dan
AU - Willem, Michael
AU - Werner, Georg
AU - Pettkus, Nadine
AU - Brunner, Bettina
AU - Sülzen, Alice
AU - Nuscher, Brigitte
AU - Hampel, Heike
AU - Xiang, Xianyuan
AU - Feederle, Regina
AU - Tahirovic, Sabina
AU - Park, Joshua I.
AU - Prorok, Rachel
AU - Mahon, Cathal
AU - Liang, Chun Chi
AU - Shi, Ju
AU - Kim, Do Jin
AU - Sabelström, Hanna
AU - Huang, Fen
AU - Di Paolo, Gilbert
AU - Simons, Mikael
AU - Lewcock, Joseph W.
AU - Haass, Christian
N1 - Publisher Copyright:
© 2020 The Authors. Published under the terms of the CC BY 4.0 license
PY - 2020/4/7
Y1 - 2020/4/7
N2 - Triggering receptor expressed on myeloid cells 2 (TREM2) is essential for the transition of homeostatic microglia to a disease-associated microglial state. To enhance TREM2 activity, we sought to selectively increase the full-length protein on the cell surface via reducing its proteolytic shedding by A Disintegrin And Metalloproteinase (i.e., α-secretase) 10/17. We screened a panel of monoclonal antibodies against TREM2, with the aim to selectively compete for α-secretase-mediated shedding. Monoclonal antibody 4D9, which has a stalk region epitope close to the cleavage site, demonstrated dual mechanisms of action by stabilizing TREM2 on the cell surface and reducing its shedding, and concomitantly activating phospho-SYK signaling. 4D9 stimulated survival of macrophages and increased microglial uptake of myelin debris and amyloid β-peptide in vitro. In vivo target engagement was demonstrated in cerebrospinal fluid, where nearly all soluble TREM2 was 4D9-bound. Moreover, in a mouse model for Alzheimer's disease-related pathology, 4D9 reduced amyloidogenesis, enhanced microglial TREM2 expression, and reduced a homeostatic marker, suggesting a protective function by driving microglia toward a disease-associated state.
AB - Triggering receptor expressed on myeloid cells 2 (TREM2) is essential for the transition of homeostatic microglia to a disease-associated microglial state. To enhance TREM2 activity, we sought to selectively increase the full-length protein on the cell surface via reducing its proteolytic shedding by A Disintegrin And Metalloproteinase (i.e., α-secretase) 10/17. We screened a panel of monoclonal antibodies against TREM2, with the aim to selectively compete for α-secretase-mediated shedding. Monoclonal antibody 4D9, which has a stalk region epitope close to the cleavage site, demonstrated dual mechanisms of action by stabilizing TREM2 on the cell surface and reducing its shedding, and concomitantly activating phospho-SYK signaling. 4D9 stimulated survival of macrophages and increased microglial uptake of myelin debris and amyloid β-peptide in vitro. In vivo target engagement was demonstrated in cerebrospinal fluid, where nearly all soluble TREM2 was 4D9-bound. Moreover, in a mouse model for Alzheimer's disease-related pathology, 4D9 reduced amyloidogenesis, enhanced microglial TREM2 expression, and reduced a homeostatic marker, suggesting a protective function by driving microglia toward a disease-associated state.
KW - Alzheimer's disease
KW - amyloid β-peptide
KW - microglia
KW - therapeutic antibody
KW - TREM2
UR - http://www.scopus.com/inward/record.url?scp=85081240935&partnerID=8YFLogxK
U2 - 10.15252/emmm.201911227
DO - 10.15252/emmm.201911227
M3 - Article
C2 - 32154671
AN - SCOPUS:85081240935
SN - 1757-4676
VL - 12
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 4
M1 - e11227
ER -